Platelet reactivity and response to aspirin in subjects with the metabolic syndrome

American Heart Journal

Volumn 156, Issue 5, 2008, Pages 1002.e1-1002.e7

  Vaduganathan, Muthiah ^a,b   Alviar, Carlos L ^a,b   Arikan, Mehmet E ^a,b   Tellez, Armando ^a,b   Guthikonda, Sadishar ^a,b   DeLao, Timothy ^a,b   Granada, Juan F ^a,b   Kleiman, Neal S ^a,b   Ballantyne, Christie M ^a,c   Lev, Eli I ^a,b  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; FIBRINOGEN RECEPTOR; PADGEM PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HYPOTHESIS; MALE; MEDICAL RESEARCH; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHEAR STRESS; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT RESPONSE;

EID: 54349122468     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.08.002     Document Type: Article

References (44)

1. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication No. 01-3670 (2001), US Dept. of Health and Human Services, National Institutes of Health, Bethesda (Md)
2. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
3. Campbell C.Y., Nasir K., and Blumenthal R.S. Metabolic syndrome, subclinical coronary atherosclerosis and cardiovascular risk. Am Heart Hosp J 3 (2005) 105-110
4. Shields T.M., and Hennekens C.H. Management of metabolic syndrome: aspirin. Endocrinol Metab Clin North Am 33 (2004) 577-593
5. Scheen A.J. Management of the metabolic syndrome. Minerva Endocrinol 29 (2004) 31-45
6. Wagh A., and Stone N.J. Treatment of metabolic syndrome. Expert Rev Cardiovasc Ther 2 (2004) 213-228
7. Buchanan M.R., and Brister S.J. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 11 (1995) 221-227
8. Eikelboom J.W., Hirsh J., Weitz J.I., et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
9. Gum P.A., Kottke-Marchant K., Welsh P.A., et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
10. Chen W.H., Lee P.Y., Ng W., et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43 (2004) 1122-1126
11. Krasopoulos G., Brister S.J., Beattie W.S., et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336 (2008) 195-198
12. Lev E., Patel R., Maresh K.J., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
13. Lordkipanidzé M., Pharand C., Schampaert E., et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 28 (2007) 1702-1708
14. Keating F.K., Whitaker D.A., Kabbani S.S., et al. Relation of augmented platelet reactivity to the magnitude of distribution of atherosclerosis. Am J Cardiol 94 (2004) 725-728
15. Tschoepe D., Roesen P., Schwippert B., et al. Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis. Semin Thromb Hemost 19 (1993) 122-128
16. Yan Y., and Phillips D.R. Aspirin response and failure in diabetic patients with cardiovascular disease. Curr Opin Pharmacol 5 (2005) 190-197
17. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54 (2005) 2430-2435
18. Watala C., Golanski J., Pluta J., et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicyclic acid (aspirin)-its relation to metabolic control. Thromb Res 113 (2004) 101-113
19. Takahashi S., Ushida M., Komine R., et al. Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res 119 (2007) 517-524
20. Tamminen M., Lassila R., Westerbacka J., et al. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicyclic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 27 (2003) 907-911
21. Kahraman G., Sahin T., Kilic T., et al. The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. Int J Cardiol 115 (2007) 391-396
22. Michelson A.D., Barnard M.R., Krueger L.A., et al. Evaluation of platelet function by flow cytometry. Methods 21 (2000) 259-270
23. Robinson M.S., Mackie I.J., Machin S.J., et al. Two color analysis of reticulated platelets. Clin Lab Haematol 22 (2000) 211-213
24. Shenkman B., Savion N., Dardik R., et al. Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor. Thromb Res 99 (2000) 353-361
25. Vaidyula V.R., Boden G., and Rao A.K. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets 17 (2006) 577-585
26. Schneider D.J. Abnormalities of coagulation, platelet function, and fibrinolysis associated with syndromes of insulin resistance. Coron Artery Dis 16 (2005) 473-476
27. Davi G., Guagnano M.T., Ciabattoni G., et al. Platelet Activation in Obese Women: role of Inflammation and Oxidant Stress. JAMA 288 (2002) 2008-2014
28. Arteaga R.B., Chirinos J.A., Soriano A.O., et al. Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol 98 (2006) 70-74
29. Serebruany V.L., Malinin A., Ong S., et al. Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease. J Thromb Thrombolysis 25 (2008) 207-213
30. Zimmermann N., Kienzle P., Weber A.A., et al. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 121 (2001) 982-984
31. Zimmermann N., Wenk A., Kim U., et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 108 (2003) 542-547
32. Guthikonda S., Lev E.I., Patel R., et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 5 (2007) 490-496
33. Tavil Y., Sen N., Yazici H.U., et al. Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res 120 (2007) 245-250
34. DiChiara J., Bliden K.P., Tantry U.S., et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 56 (2007) 3014-3019
35. Winocour P.D. Platelet abnormalities in diabetes mellitus. Diabetes 41 Suppl 2 (1992) 26-31
36. Trovati M., Mularoni E.M., Burzacca S., et al. Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes 44 (1995) 1318-1322
37. Westerbacka J., Yki-Jarvinen H., Turpeinen A., et al. Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol 22 (2002) 167-172
38. Watala C., Pluta J., Golanski J., et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 83 (2005) 148-158
39. Modica A., Karlsson F., and Mooe T. Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. J Thromb Haemost 5 (2007) 507-511
40. Michelson A.D., Barnard M.R., Krueger L.A., et al. Flow cytometry. In: Michelson A.D. (Ed). Platelets (2002), Academic Press, San Diego, CA 297-315
41. Kamath S., Blann A.D., and Lip G.Y. Platelet activation: assessment and quantification. Eur Heart J 22 (2001) 1561-1571
42. Osende J.I., Fuster V., Lev E.I., et al. Testing platelet activation with a shear-dependent platelet function test versus aggregation based tests, Relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Circulation 103 (2001) 1488-1491
43. Berger J.S., Roncaglioni M.C., Avanzini F., et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295 (2006) 306-313
44. Sacco M., Pellegrini F., Roncaglioni M.C., et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 26 (2003) 3264-3272